ADVFN Logo ADVFN

We could not find any results for:
Make sure your spelling is correct or try broadening your search.

Trending Now

Toplists

It looks like you aren't logged in.
Click the button below to log in and view your recent history.

Sign Up

Already a member? Sign in

Interactive Brokers

Interactive Brokers
Market Data
News
Trading Tools
Markets
Discover

Hot Features

Follow Feed

Connect with traders and investors in our Follow Feed community.

Options Flow

Explore comprehensive options data and use advanced filters with Options Flow.

Monitor

Organize and monitor your stock and asset watchlist with Monitor.
AI Sign In Premium IconPremium Help Menu
S&P 500
5,505.00
0.00%
US Tech 100
19,210.00
1.05%
Dow Jones
40,287.53
0.00%
Brent Oil
81.135
-1.39%
Bitcoin
67,791.41
-0.54%
Registration Strip Icon for smarter Trade smarter, not harder: Unleash your inner pro with our toolkit and live discussions.
Get Started
  1. Home
  2. Investing
  3. Stocks
  4. USA
  5. NASDAQ
  6. Tenax Therapeutics Inc (TENX)

  7. Tenax Therapeutics Inc (TENX) News

TENX

Tenax Therapeutics (TENX)

Tenax Therapeutics Inc
Date:
Sort by:
 Showing the most relevant articles for your search:NASDAQ:TENX
DateTimeSourceHeadlineSymbolCompany
06/13/20244:32PMEdgar (US Regulatory)Form 8-K - Current reportNASDAQ:TENXTenax Therapeutics Inc
05/24/20244:31PMEdgar (US Regulatory)Form DEFA14A - Additional definitive proxy soliciting materials and Rule 14(a)(12) materialNASDAQ:TENXTenax Therapeutics Inc
05/21/20245:01PMEdgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:TENXTenax Therapeutics Inc
05/21/20245:00PMEdgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:TENXTenax Therapeutics Inc
05/14/20244:01PMEdgar (US Regulatory)Form 10-Q - Quarterly report [Sections 13 or 15(d)]NASDAQ:TENXTenax Therapeutics Inc
05/14/20249:01AMEdgar (US Regulatory)Form 8-K - Current reportNASDAQ:TENXTenax Therapeutics Inc
05/14/20248:00AMGlobeNewswire Inc.Tenax Therapeutics Reports First Quarter 2024 Financial Results and Provides a Corporate UpdateNASDAQ:TENXTenax Therapeutics Inc
04/30/20247:30AMGlobeNewswire Inc.Tenax Therapeutics Announces New U.S. Patent Covering the Use of Levosimendan in Pulmonary Hypertension with Heart Failure with Preserved Ejection Fraction (PH-HFpEF)NASDAQ:TENXTenax Therapeutics Inc
04/09/20248:30AMGlobeNewswire Inc.Tenax Therapeutics to Host KOL Event: “LEVEL Setting: the Scientific Rationale for Levosimendan as a Potential First Treatment for PH-HFpEF, and the Ongoing Phase 3 LEVEL Study”NASDAQ:TENXTenax Therapeutics Inc
03/28/20248:30AMGlobeNewswire Inc.Tenax Therapeutics Provides Business and Clinical Development Updates with Full Year 2023 Financial ResultsNASDAQ:TENXTenax Therapeutics Inc
03/12/20248:30AMGlobeNewswire Inc.Tenax Therapeutics to Present at the 36th Annual Roth ConferenceNASDAQ:TENXTenax Therapeutics Inc
02/29/20249:00AMGlobeNewswire Inc.Tenax Therapeutics Announces Oral Presentation of Levosimendan for the Treatment of PH-HFpEF at THT 2024NASDAQ:TENXTenax Therapeutics Inc
02/26/20244:31PMEdgar (US Regulatory)Form 424B3 - Prospectus [Rule 424(b)(3)]NASDAQ:TENXTenax Therapeutics Inc
02/26/20244:31PMEdgar (US Regulatory)Form 424B3 - Prospectus [Rule 424(b)(3)]NASDAQ:TENXTenax Therapeutics Inc
02/23/20244:30PMEdgar (US Regulatory)Form 8-K - Current reportNASDAQ:TENXTenax Therapeutics Inc
02/21/20244:32PMEdgar (US Regulatory)Form 424B3 - Prospectus [Rule 424(b)(3)]NASDAQ:TENXTenax Therapeutics Inc
02/21/20244:30PMEdgar (US Regulatory)Form 424B3 - Prospectus [Rule 424(b)(3)]NASDAQ:TENXTenax Therapeutics Inc
02/20/20244:01PMEdgar (US Regulatory)Form SC 13G - Statement of acquisition of beneficial ownership by individualsNASDAQ:TENXTenax Therapeutics Inc
02/20/20248:33AMEdgar (US Regulatory)Form 8-K - Current reportNASDAQ:TENXTenax Therapeutics Inc
02/20/20248:30AMGlobeNewswire Inc.Tenax Therapeutics Announces Global License Amendment that Significantly Expands Rights to LevosimendanNASDAQ:TENXTenax Therapeutics Inc
02/16/202411:28AMEdgar (US Regulatory)Form SC 13G - Statement of acquisition of beneficial ownership by individualsNASDAQ:TENXTenax Therapeutics Inc
02/15/20247:36PMEdgar (US Regulatory)Form SC 13G - Statement of acquisition of beneficial ownership by individualsNASDAQ:TENXTenax Therapeutics Inc
02/14/20242:58PMEdgar (US Regulatory)Form SC 13G/A - Statement of acquisition of beneficial ownership by individuals: [Amend]NASDAQ:TENXTenax Therapeutics Inc
02/13/20244:32PMEdgar (US Regulatory)Form 424B3 - Prospectus [Rule 424(b)(3)]NASDAQ:TENXTenax Therapeutics Inc
02/12/20244:46PMEdgar (US Regulatory)Form 8-K - Current reportNASDAQ:TENXTenax Therapeutics Inc
02/09/20245:00PMEdgar (US Regulatory)Form 424B4 - Prospectus [Rule 424(b)(4)]NASDAQ:TENXTenax Therapeutics Inc
02/08/20244:51PMEdgar (US Regulatory)Form 424B3 - Prospectus [Rule 424(b)(3)]NASDAQ:TENXTenax Therapeutics Inc
02/08/20248:16AMGlobeNewswire Inc.Tenax Therapeutics Announces Pricing of Approximately $9 Million Public OfferingNASDAQ:TENXTenax Therapeutics Inc
02/08/202412:15AMEdgar (US Regulatory)Form EFFECT - Notice of EffectivenessNASDAQ:TENXTenax Therapeutics Inc
02/07/20248:01PMGlobeNewswire Inc.Tenax Therapeutics Enrolls First Patient in Phase 3 LEVEL Study Evaluating TNX-103 (Oral Levosimendan) for the Treatment of Pulmonary Hypertension in Heart Failure with Preserved Ejection Fraction (PH-HFpEF)NASDAQ:TENXTenax Therapeutics Inc
 Showing the most relevant articles for your search:NASDAQ:TENX

Your Recent History

USOTC
KBLB
Kraig Biocraft Laborator... (QB)
USOTC
BIEL
Bioelectronics (PK)
USOTC
SPZI
Spooz (PK)
USOTC
HIRU
Hiru (PK)
USOTC
RONN
Ronn Motor (PK)
USOTC
VPLM
Voip Pal Com (QB)
COIN
BTCUSD
Bitcoin
USOTC
AABB
Asia Broadband (PK)
NASDAQ
LWLG
Lightwave Logic
NASDAQ
COOP
Mr Cooper
NASDAQ
AVXL
Anavex Life Sciences
USOTC
BLEG
Branded Legacy (PK)
USOTC
NWBO
Northwest Biotherapeutics (QB)
NASDAQ
AMRN
Amarin
NASDAQ
MAXN
Maxeon Solar Technologies
USOTC
NSAV
Net Savings Link (PK)
Delayed Upgrade Clock
ADVFN Logo
InvestorsHub

United States
Company
Business
Popular
Get The App
App Store
Google Play

Support: 1-888-992-3836 | support@advfn.com

By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions

© 2024 ADVFN PLC - All Rights Reserved